BluePath Capital Management’s PAVmed PAVM Stock Holding History

BluePath Capital Management’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-65	Closed	-$8.55K	–	262
2023 Q3	$8.55K	Buy	+65	New	+$10.1K	0.01%	334

Other funds holding PAVM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

XML Financial Bethesda, Maryland $1.24B AUM 20.4% 1-Year Est. Return

BluePath Capital Management's PAVM Position: Q4 2023 in Review

BluePath Capital Management sold out of PAVmed (PAVM) in Q4 2023, closing a stake of 65 shares — an estimated $8.55K sold.

BluePath Capital Management first reported a position in PAVM in Q3 2023 and held it in 1 quarter. The position peaked at $8.55K in Q3 2023. 23 funds tracked by Wall St. Rank hold PAVM as of Q4 2023.

BluePath Capital Management reported no remaining PAVmed position as of Q4 2023 after selling out during the quarter.
BluePath Capital Management sold 65 PAVmed shares in Q4 2023, an estimated $8.55K.
BluePath Capital Management first reported a position in PAVmed in Q3 2023 and held it in 1 quarter.
BluePath Capital Management's PAVmed position peaked at $8.55K in Q3 2023.
23 funds tracked by Wall St. Rank held PAVmed as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.